article thumbnail

Keeping tabs on Covid-19: Starpharma creates slow release remdesivir nanoparticl…

The Pharma Data

In an effort to slow the spread of the disease and prevent a second wave, pharma companies around the world are continuously looking to advance new methods of treatment. This week’s round up dives into developments from companies based in Australia and the US. acting, water-soluble version of remdesivir.

article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

As life science operates globally, the vision for the business was always to bring aptamers as an antibody alternative to researchers worldwide. Addressing this need in the market has allowed us penetration to work with 75% of the top twenty pharma companies. Optimer binders are engineered to overcome these problems.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry.

article thumbnail

Big tobacco’s PMI makes another pharma foray with Vectura deal

pharmaphorum

Tobacco giant Philip Morris International (PMI) has doubled down on its move into the pharmaceutical sector, following up its recent acquisition of Fertin Pharma with a deal to buy Vectura for around £1 billion ($1.38 The UK pharma company says it has now withdrawn its recommendation to shareholders to accept that deal.